[{"orgOrder":0,"company":"Genuine Research Center, Egypt","sponsor":"Chemipharm","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"EGYPT","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Modafinil","moa":"Dopamine transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Genuine Research Center, Egypt","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genuine Research Center, Egypt \/ Chemipharm","highestDevelopmentStatusID":"6","companyTruncated":"Genuine Research Center, Egypt \/ Chemipharm"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Modafinil","moa":"Dopamine transporter","graph1":"Sleep","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Apotex Inc"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Modafinil","moa":"Dopamine transporter","graph1":"Sleep","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Neuraxpharm"}]

Find Clinical Drug Pipeline Developments & Deals for DSSTox_CID_3329

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Acquiring the US rights to PROVIGIL (modafinil) and NUVIGIL (armodafinil) indicated to improve wakefulness in adult patients marks a strategic milestone for Apotex.

                          Product Name : Provigil

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          January 09, 2025

                          Lead Product(s) : Modafinil

                          Therapeutic Area : Sleep

                          Highest Development Status : Approved FDF

                          Sponsor : Apotex Inc

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Neuraxpharm has acquired these products Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of EDS in adults with narcolepsy.

                          Product Name : Provigil

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          January 07, 2025

                          Lead Product(s) : Modafinil

                          Therapeutic Area : Sleep

                          Highest Development Status : Approved FDF

                          Sponsor : Neuraxpharm

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          Genuine Research Center, Egypt

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Genuine Research Center, Egypt

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Modafinil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 11, 2023

                          Lead Product(s) : Modafinil

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Chemipharm

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank